VISCHER represents the sellers of GlycoVaxyn AG, in its sale to GlaxoSmithKline (GSK) for a consideration of $190 million, valuing this privately held Swiss vaccine company in Schlieren-Zurich at $212 million in total. GlycoVaxyn’s innovative biological conjugation platform originates from ETH Zurich and enables the development of a new generation of conjugate vaccines against major bacterial infections. VISCHER has been assisting several financing rounds raising approximately CHF 50 million of equity funding with top-tier private investors including Sofinnova Partners, Index Ventures and Edmond de Rothschild Investment Partners. VISCHER has also been assisting the Company's plan to go public on the Swiss Stock Exchange in spring 2015; this IPO was close to completion prior to the sale to GSK. The VISCHER-team is led by Dr. Matthias Staehelin (partner), Dr. Stefan Grieder (partner, both Corporate) and Nadia Tarolli Schmidt (partner, Tax) with Christian Wyss (partner), Moritz Jäggy (Associate), Dania Salvisberg-Schneider (Associate) and Ruben Masar (Associate, all Corporate).